pioglitazone has been researched along with empagliflozin in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (82.35) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y | 1 |
| Broedl, UC; Jones, R; Kovacs, CS; Rattunde, H; Seshiah, V; Swallow, R; Woerle, HJ | 1 |
| Broedl, UC; Macha, S; Mattheus, M; Pinnetti, S; Woerle, HJ | 1 |
| Broedl, UC; Christiansen, AV; Kim, G; Kovacs, CS; Merker, L; Roux, F; Salsali, A; Seshiah, V; Stella, P; Woerle, HJ | 1 |
| Abdul-Ghani, M; Chilton, R; Clarke, G; DeFronzo, RA; Norton, L; Ryder, RE | 1 |
| Bloomgarden, Z | 1 |
| Farooq, S; Islam, N; Kiran, Z; Rashid, O | 1 |
| Abdul-Ghani, M; Chilton, R; DeFronzo, RA; Del Prato, S | 1 |
| Schernthaner, G; Schernthaner, GH; Schernthaner-Reiter, MH | 1 |
| Crowe, S; Hach, T; Lee, J; Nishimura, R; Salsali, A; Woerle, HJ; Yoon, KH | 1 |
| Ampudia-Blasco, FJ; Ariño, B; Giljanovic Kis, S; Naderali, E; Pérez, A; Pfarr, E; Romera, I | 1 |
| Eleftheriadou, I; Grigoropoulou, P; Kokkinos, A; Liatis, S; Liberopoulos, E; Tentolouris, N | 1 |
| Abdul-Ghani, M; Chilton, R; DeFronzo, RA; Del Prato, S; Ryder, REJ; Singh, R | 1 |
| Abdullah, AM; Fakhre, NA; M Amin, KF | 1 |
| Bhutani, R; Bodla, RB; Kant, R; Kapoor, G | 1 |
| Ashida, K; Hasuzawa, N; Iwata, S; Kitajima, Y; Moritaka, K; Motomura, S; Nagayama, A; Nomura, M; Ozono, S; Sonezaki, A; Takahashi, H; Watanabe, M; Yasuda, J; Yoshinobu, S | 1 |
| Ajdarkosh, H; Attaran, F; Emami, S; Ismail-Beigi, F; Khamseh, ME; Khoonsari, M; Malek, M; Sohrabi, M | 1 |
3 review(s) available for pioglitazone and empagliflozin
| Article | Year |
|---|---|
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary | 2020 |
Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Drug Therapy, Combination; Evidence-Based Medicine; Glucosides; Humans; Hypoglycemic Agents; Membrane Transport Modulators; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2016 |
Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Metformin; Pioglitazone; Sodium-Glucose Transporter 2 | 2018 |
6 trial(s) available for pioglitazone and empagliflozin
| Article | Year |
|---|---|
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Treatment Outcome; Weight Loss | 2014 |
Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers.
Topics: Adolescent; Adult; Area Under Curve; Benzhydryl Compounds; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Glucosides; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Young Adult | 2015 |
Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones; Treatment Outcome; Young Adult | 2015 |
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Electrolytes; Endpoint Determination; Glucosides; Glycated Hemoglobin; Hospitalization; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Treatment Outcome | 2016 |
Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.
Topics: Asia; Asian People; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Thiazolidinediones; Treatment Outcome | 2016 |
Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Iran; Non-alcoholic Fatty Liver Disease; Pioglitazone; Single-Blind Method; Ventricular Function, Left | 2023 |
8 other study(ies) available for pioglitazone and empagliflozin
| Article | Year |
|---|---|
Glycemic control and the heart: it matters how you get there.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus; Glucosides; Humans; Hypoglycemic Agents; Liraglutide; Outcome Assessment, Health Care; Pioglitazone; Thiazolidinediones | 2016 |
Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin.
Topics: Adult; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2016 |
EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones | 2016 |
Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus.
Topics: Aged; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Disease Susceptibility; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Infections; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2016 |
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Thiazolidinediones; Treatment Outcome | 2017 |
Mean centering-triple divisor and ratio derivative-zero crossing for simultaneous determination of some diabetes drugs in their quaternary mixture with severely overlapping spectra.
Topics: Algorithms; Analysis of Variance; Benzhydryl Compounds; Glucosides; Hypoglycemic Agents; Linagliptin; Metformin; Pioglitazone; Spectrophotometry, Ultraviolet; Tablets | 2019 |
Optimization of a single HPLC-PDA method for quantifying Metformin, Gliclazide, Pioglitazone, Dapagliflozin, Empagliflozin, Saxagliptin, Linagliptin and Teneligliptin using central composite design.
Topics: Adamantane; Benzhydryl Compounds; Chromatography, High Pressure Liquid; Dipeptides; Dose-Response Relationship, Drug; Gliclazide; Glucosides; Linagliptin; Metformin; Molecular Structure; Pioglitazone; Pyrazoles; Software; Structure-Activity Relationship; Thiazolidines | 2019 |
Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy.
Topics: Benzhydryl Compounds; Bone Marrow Transplantation; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Leptin; Lipodystrophy; Pioglitazone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2021 |